DK0956001T3 - Fremstilling af stabile formuleringer af lipid-nukleinsyre-komplekser til virksom in-vivo indgivelse - Google Patents

Fremstilling af stabile formuleringer af lipid-nukleinsyre-komplekser til virksom in-vivo indgivelse

Info

Publication number
DK0956001T3
DK0956001T3 DK97949417.6T DK97949417T DK0956001T3 DK 0956001 T3 DK0956001 T3 DK 0956001T3 DK 97949417 T DK97949417 T DK 97949417T DK 0956001 T3 DK0956001 T3 DK 0956001T3
Authority
DK
Denmark
Prior art keywords
lipid
preparation
effective
nucleic acid
acid complex
Prior art date
Application number
DK97949417.6T
Other languages
Danish (da)
English (en)
Inventor
Demetrios Papahadjopoulos
Deelung Hong
Weiwen Zheng
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK0956001T3 publication Critical patent/DK0956001T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK97949417.6T 1996-11-12 1997-11-10 Fremstilling af stabile formuleringer af lipid-nukleinsyre-komplekser til virksom in-vivo indgivelse DK0956001T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3057896P 1996-11-12 1996-11-12
PCT/US1997/020690 WO1998020857A1 (en) 1996-11-12 1997-11-10 Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery

Publications (1)

Publication Number Publication Date
DK0956001T3 true DK0956001T3 (da) 2012-10-22

Family

ID=21854872

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97949417.6T DK0956001T3 (da) 1996-11-12 1997-11-10 Fremstilling af stabile formuleringer af lipid-nukleinsyre-komplekser til virksom in-vivo indgivelse

Country Status (9)

Country Link
US (4) US6071533A (enExample)
EP (1) EP0956001B1 (enExample)
JP (2) JP2001510457A (enExample)
AU (1) AU729655B2 (enExample)
CA (1) CA2271325A1 (enExample)
DK (1) DK0956001T3 (enExample)
ES (1) ES2392246T3 (enExample)
PT (1) PT956001E (enExample)
WO (1) WO1998020857A1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
JP2001510457A (ja) * 1996-11-12 2001-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インビボ送達に有効な、脂質―核酸複合体の安定な製剤の調製
NZ333334A (en) * 1997-04-17 2001-06-29 Frank L Sorgi Delivery system for gene therapy to the brain
US6749863B1 (en) 1997-11-19 2004-06-15 Georgetown University Targeted liposome gene delivery
ATE237312T1 (de) * 1998-07-20 2003-05-15 Protiva Biotherapeutics Inc In liposomen verkapselte nukleinsäurekomplexe
US7479276B1 (en) 1999-02-22 2009-01-20 Synergene Therapeutics, Inc. Antibody fragment-targeted immunoliposomes for systemic gene delivery
US9034329B2 (en) * 1999-02-22 2015-05-19 Georgetown University Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
US7780882B2 (en) * 1999-02-22 2010-08-24 Georgetown University Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
CA2362485A1 (en) * 1999-03-02 2000-09-08 The Liposome Company, Inc. Encapsulation of bioactive complexes in liposomes
EP1754488A1 (en) * 1999-05-24 2007-02-21 Introgen Therapeutics, Inc. Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
WO2000071096A2 (en) * 1999-05-24 2000-11-30 Introgen Therapeutics, Inc. Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
US7067111B1 (en) * 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US7189705B2 (en) * 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
US10293056B1 (en) * 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
IL153218A0 (en) * 2000-06-02 2003-07-06 Univ Texas Ethylenedicysteine (ec) -drug conjugates
AU2001294890A1 (en) * 2000-09-25 2002-04-02 Board Of Regents, The University Of Texas System Pei: dna vector formulations for in vitro and in vivo gene delivery
US20020146829A1 (en) * 2000-11-29 2002-10-10 Aventis Pharmaceuticals Products Inc. Neutral and anionic colloidal particles for gene delivery
ES2312608T3 (es) * 2001-04-02 2009-03-01 Georgetown University Procedimiento simplificado y mejorado para preparar un polipejo o inmunoliposoma dirigido contra un anticuerpo o un fragmento de anticuerpo para la administracion sistemica de un agente de diagnostico o terapeutico.
CA2444483A1 (en) * 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Diagnostic imaging compositions, their methods of synthesis and use
US20030203865A1 (en) * 2001-04-30 2003-10-30 Pierrot Harvie Lipid-comprising drug delivery complexes and methods for their production
EP1389182A1 (en) * 2001-05-15 2004-02-18 Transgene S.A. Complexes for transferring substances of interest into a cell
FR2829136B1 (fr) * 2001-08-29 2006-11-17 Aventis Pharma Sa Derives lipidiques d'aminoglycosides
US20030049203A1 (en) * 2001-08-31 2003-03-13 Elmaleh David R. Targeted nucleic acid constructs and uses related thereto
US7261875B2 (en) * 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
KR100466254B1 (ko) * 2002-02-25 2005-01-14 한국과학기술원 세포내 전달을 위한 올리고뉴클레오티드와 친수성 고분자로 구성되는 유전자 전달용 접합체, 고분자 전해질 복합 미셀 및 그의 제조방법
CA2752143C (en) * 2002-05-15 2014-09-23 Sutter West Bay Hospitals Delivery of nucleic acid-like compounds
US20040137064A1 (en) * 2003-01-15 2004-07-15 Lewis David L. Compositions and processes using siRNA, amphipathic compounds and polycations
WO2003106636A2 (en) * 2002-06-14 2003-12-24 Mirus Corporation Novel methods for the delivery of polynucleotides to cells
CN101985443A (zh) * 2002-11-07 2011-03-16 得克萨斯大学体系董事会 乙二半胱氨酸（ec）-药物结合物、组合物及用于组织特异性疾病显像的方法
ES2371913T3 (es) 2003-01-22 2012-01-11 Duke University Constructos mejorados para expresar polipéptidos lisosomales.
WO2005037858A2 (en) * 2003-10-16 2005-04-28 University Of Massachusetts Template-directed assembly of receptor signaling complexes
US9050378B2 (en) * 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
US20050261221A1 (en) * 2004-03-01 2005-11-24 Li Wang Compositions and methods for enhanced delivery of compounds via transfection complexes
AU2005244262A1 (en) * 2004-04-09 2005-11-24 Biodelivery Sciences International, Inc. Nucleotide-cochleate compositions and methods of use
WO2006074108A2 (en) * 2004-12-30 2006-07-13 Hauser Todd M Compositions and methods for modulating gene expression using self-protected oligonucleotides
KR20070104575A (ko) * 2005-01-28 2007-10-26 교와 핫꼬 고교 가부시끼가이샤 표적 유전자의 발현을 억제하는 조성물
US20090175930A1 (en) * 2006-01-11 2009-07-09 Nobuhiro Yagi Composition Suppressing The Expression of Target Gene in Eyeball and Medicament For Treating of Disease in Eyeball
WO2007112107A2 (en) * 2006-03-24 2007-10-04 Gencia Corporation Synthetic lipid rafts and methods of use
US8758723B2 (en) 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
WO2007127803A2 (en) 2006-04-25 2007-11-08 The Regents Of The University Of California Administration of growth factors for the treatment of cns disorders
EP2023949A4 (en) * 2006-04-26 2009-08-26 Univ California COMPOSITIONS AND METHODS FOR CONVECTION-REINFORCED RELEASE OF NEUROTHERAPEUTICS WITH HIGH MOLECULAR WEIGHT
JP2009537526A (ja) 2006-05-15 2009-10-29 ジョージタウン・ユニバーシティ 治療もしくは診断剤の全身投与のための抗体もしくは抗体断片標的化免疫リポソームの製造およびその使用
US8541190B2 (en) * 2006-06-28 2013-09-24 Robert M. Weis Methods and materials for in vitro analysis and/or use of membrane-associated proteins, portions thereof or variants thereof
US20080213349A1 (en) * 2006-09-11 2008-09-04 Deepak Ramesh Thakker Liposome Complexes Containing Pharmaceutical Agents and Methods
US20100035974A1 (en) * 2006-10-04 2010-02-11 Centre National De La Recherche Scientifique (Cnrs Compositions comprising a sirna and lipidic 4,5-disubstituted 2-deoxystreptamine ring aminoglycoside derivatives and uses thereof
US10925977B2 (en) * 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
US8367052B2 (en) 2007-03-26 2013-02-05 General Regeneratives Holdings Inc. Methods for promoting protection and regeneration of bone marrow using CXCL9 and anti-CXCL9 antibodies
WO2009009054A1 (en) * 2007-07-09 2009-01-15 Georgetown University Methods for generating immune response using cationic-liposome-mediated nucleic acid delivery
CA2727428A1 (en) * 2008-06-19 2009-12-23 Nippon Shinyaku Co., Ltd. Drug carrier
AU2009330859B2 (en) * 2008-12-26 2013-06-20 Samyang Holdings Corporation Pharmaceutical composition containing an anionic drug, and a production method therefor
WO2011123479A1 (en) 2010-03-29 2011-10-06 Academia Sinica Quantitative measurement of nano / micro particle endocytosis with cell mass spectrometry
RU2436583C1 (ru) * 2010-07-06 2011-12-20 Общество с ограниченной ответственностью "ВИТАЛАНГ" Противовирусное средство
JP5760562B2 (ja) * 2011-03-22 2015-08-12 セイコーエプソン株式会社 読取装置および読取方法
EP2760463B1 (en) 2011-09-20 2018-11-21 The University of North Carolina At Chapel Hill Regulation of sodium channels by plunc proteins
US9238865B2 (en) * 2012-02-06 2016-01-19 Asm Ip Holding B.V. Multiple vapor sources for vapor deposition
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
BR112018017144A2 (pt) 2016-02-22 2019-01-15 Univ North Carolina Chapel Hill inibidores de peptídeo de canais de cálcio
US11788190B2 (en) 2019-07-05 2023-10-17 Asm Ip Holding B.V. Liquid vaporizer
AU2020311399A1 (en) * 2019-07-10 2022-02-17 University Of Washington Non-viral immuno-targeting
US11946136B2 (en) 2019-09-20 2024-04-02 Asm Ip Holding B.V. Semiconductor processing device
GB202004254D0 (en) 2020-03-24 2020-05-06 Puridify Ltd Characterization of gene therapy vectors
CN118302157A (zh) * 2021-09-30 2024-07-05 日油株式会社 具有细胞靶向性的脂质纳米颗粒
DE102023001946A1 (de) * 2023-05-12 2024-11-14 Friedrich-Schiller-Universität Jena, Körperschaft des öffentlichen Rechts Nanopartikel für den Transport von Wirkstoffen mit anionischen Gruppen, Verfahren zu deren Herstellung und deren Verwendung
CN119490670A (zh) * 2024-11-26 2025-02-21 山东大学 一种慢病毒转染增强纳米颗粒及其制备方法与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003797A1 (en) * 1986-11-28 1988-06-02 The Liposome Company, Inc. Phospholipid composition
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
ATE260679T1 (de) * 1992-04-03 2004-03-15 Univ California Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid
US6113946A (en) * 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
FR2722506B1 (fr) * 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
WO1996014864A1 (en) 1994-11-09 1996-05-23 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5736392A (en) * 1995-06-07 1998-04-07 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US5851818A (en) 1996-05-31 1998-12-22 Sequus Pharmaceuticals, Inc. Condensed plasmid-liposome complex for transfection
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
JP2001510457A (ja) 1996-11-12 2001-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インビボ送達に有効な、脂質―核酸複合体の安定な製剤の調製

Also Published As

Publication number Publication date
US6071533A (en) 2000-06-06
US6410049B1 (en) 2002-06-25
HK1024864A1 (en) 2000-10-27
CA2271325A1 (en) 1998-05-22
US20020182249A1 (en) 2002-12-05
EP0956001B1 (en) 2012-09-12
EP0956001A4 (en) 2006-03-22
US7462603B2 (en) 2008-12-09
JP4551464B2 (ja) 2010-09-29
WO1998020857A1 (en) 1998-05-22
US6943027B2 (en) 2005-09-13
AU729655B2 (en) 2001-02-08
JP2001510457A (ja) 2001-07-31
US20050170509A1 (en) 2005-08-04
PT956001E (pt) 2012-12-06
EP0956001A1 (en) 1999-11-17
AU7177998A (en) 1998-06-03
ES2392246T3 (es) 2012-12-07
JP2008239631A (ja) 2008-10-09

Similar Documents

Publication Publication Date Title
DK0956001T3 (da) Fremstilling af stabile formuleringer af lipid-nukleinsyre-komplekser til virksom in-vivo indgivelse
ATE226088T1 (de) Stabile insulinformulierungen
DE69723854D1 (de) Stabile glasartige pulverformulierungen
IS2325B (is) Örgerðar samsetningar epleróns
PT769965E (pt) Formulacoes aquosas de risperidona
DE59505055D1 (de) Dermal applizierbare formulierungen von parasitiziden
DK0876131T3 (da) Sammensætninger til lægemiddelindgivelse til forbedret stabilitet af androgener
HUP0103707A3 (en) Formulation of stable oxalyplatinum solution
NO20020185L (no) Formuleringer av IL-11
DE69815263D1 (de) Stabile zubereitung auf basis von acetylsalicylsäure zur äusseren anwendung
DE59910836D1 (de) Dermal applizierbare wasserhaltige formulierungen von parasitiziden
DE69810874D1 (de) Stabile konzentrat-formulierung von vitamin c
DK0537786T3 (da) Fremstilling af en N-acylaminomethylphosphonsyre
HUP0102401A3 (en) Novel intermediates and processes for the preparation of optically active octanoic acid derivatives
BR9704595A (pt) Preparação de 3-amino-1-hidroxipropano-1, 1-ácido difosfõnico
DK0875579T3 (da) Fremstilling af L(+)-laktat
ATE197870T1 (de) Stabile festformulierungen von cyclohexenonoximether-herbiziden
DK1001962T3 (da) Fremstilling af avermectinforbindelser
DK0866787T3 (da) Aminoitril-mellemprodukt til fremstillingen af 2-hydroxyethyliminodieddikesyre
DK498388A (da) Fremgangsmaade til fremstilling af propensyrederivater
DK0782982T3 (da) Fremgangsmåde til fremstilling af o-chlormethyl-phenylglyoxylsyrederivater
DK88091A (da) Fremstilling af pentansyrederivater
DK0971919T3 (da) Fremgangsmåde til fremstilling af 4H-4-oxo-quinolizin-3-carboxylsyrederivater
DK649787A (da) Fremgangsmaade til fremstilling af optisk aktive smoersyrederivater
DK1238094T3 (da) Fremgangsmåde til fremstilling af optisk aktive cyanhyhydriner under anvendelse af R-oxynitrilase